All Merck Research Laboratories news

8 hours ago KEYTRUDA® (pembrolizumab) Treatment Results in Patients with Relapsed or Refractory Classical Hodgkin Lymphoma (cHL) Presented at 58th Annual Meeting of the American Society of Hematology - Business Wire
7 days ago FDA Grants Priority Review to Merck’s Supplemental Biologics License Application (sBLA) Seeking Approval for KEYTRUDA® (pembrolizumab) for New Indication in Microsatellite Instability-High Cancer - Business Wire
22 days ago Merck Announces Findings for Investigational Triple-Combination Chronic Hepatitis C Therapy Showing High Rates of Sustained Virologic Response in People with Genotypes 1, 2 or 3 Infection - Business Wire
23 days ago Merck’s KEYTRUDA® (pembrolizumab) Significantly Improves Overall Survival Compared to Chemotherapy in Previously Treated Patients with Advanced Bladder (Urothelial) Cancer - Business Wire
23 days ago Merck Announces Presentation of New Findings for ZEPATIER™ (Elbasvir and Grazoprevir) in Patients with Chronic Hepatitis C at The Liver Meeting® - Business Wire
A month ago Merck’s Alzheimer’s drug data fuel hopes for new treatment - Market Watch
1 months ago Protein-targeting drug shows promise for Alzheimer's treatment - FOX News
1 months ago Alzheimer’s breakthrough: 'Safe' dementia drug could fight toxic proteins - express

Create a custom search

News search supports Google type search formatting and the use of complex boolean. Wrap terms in double quotes for exact phrase matching. Click + to add multiple news search terms to this topic.